AIFF Firefly Neuroscience Inc.

Many families of children with ADHD want an alternative to stimulant medication. Many clinicians want an objective read on how an individual patient's brain is functioning. A new partnership aims to put both in the same office.Firefly Neuroscience, Inc. (NASDAQ: AIFF) and NeuroSigma, Inc. announce a strategic partnership to introduce NeuroSigma's second-generation Monarch eTNS® System to Firefly's nationwide network of Evoke™ clinician customers. Monarch is the first non-drug treatment for pediatric ADHD cleared by the U.S. Food and Drug Administration.Firefly's FDA ...

Firefly Neuroscience partners with NeuroSigma to expand access to the FDA-cleared Monarch eTNS non-drug ADHD treatment nationwide.read more...

The market is increasingly rewarding companies that can move from concept to execution and four very different small-cap stories are now entering precisely that phase. Totaligent’s (OTCID:TGNT) communications platform is going through a live, invite-only Founders Pilot; Firefly Neuroscience (NASDAQ:AIFF) is pairing AI-powered brain assessment with an FDA-cleared pediatric ADHD treatment; Fathom Holdings (NASDAQ:FTHM) and Neighborhood Intelligence (NASDAQ: NXH) are restructuring their proposed combination around real estate and digital assets; and Hyperscale Data (NYSEAMERICAN:GPUS) is converting a Michigan data-center campus from Bitcoin mining toward AI infrastructure. The common denominator is simple: the next phase is less about the pitch and more about proving the business model.

Firefly Neuroscience (NASDAQ:AIFF) is moving deeper into pediatric ADHD care through a strategic partnership with NeuroSigma, bringing NeuroSigma’s Monarch eTNS System to Firefly’s nationwide network of clinicians using its Evoke brain-function platform. The deal connects two distinct pieces of the treatment equation: Firefly’s AI-powered EEG/ERP technology for objectively assessing brain activity and Monarch, an FDA-cleared, prescription-only, non-drug treatment for children ages 7 through 12 who are not taking prescription ADHD medication.

Gainers Apimeds Pharmaceuticals (AMEX:APUS) shares rose 23.4% to $6.07 during Friday's pre-market session. The market value of their outstanding shares is at $7.4 million. Firefly Neuroscience (NASDAQ:AIFF) sharesread more...

Firefly Neuroscience, Inc. shares are trading higher Thursday after it announced a public-private partnership with the Department of Defense.read more...

The company will deploy its AI-powered EEG/ERP system to assess and treat brain injuries in service members and veterans.

SentinelOne, Tempus AI, Firefly Neuroscience, SoundHound AI, and Upstart are the five Artificial Intelligence stocks to watch today, according to MarketBeat's stock screener tool. Artificial...

SentinelOne, Tempus AI, and Firefly Neuroscience are the three Artificial Intelligence stocks to watch today, according to MarketBeat's stock screener tool. Artificial intelligence stocks are shares...